Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Income from Continuing Operations: 2016-2024

Historic Income from Continuing Operations for Dianthus Therapeutics (DNTH) over the last 7 years, with Dec 2024 value amounting to -$84.5 million.

  • Dianthus Therapeutics' Income from Continuing Operations fell 43.90% to -$36.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$125.5 million, marking a year-over-year decrease of 87.03%. This contributed to the annual value of -$84.5 million for FY2024, which is 94.65% down from last year.
  • Latest data reveals that Dianthus Therapeutics reported Income from Continuing Operations of -$84.5 million as of FY2024, which was down 94.65% from -$43.4 million recorded in FY2023.
  • Over the past 5 years, Dianthus Therapeutics' Income from Continuing Operations peaked at -$28.6 million during FY2022, and registered a low of -$84.5 million during FY2024.
  • For the 3-year period, Dianthus Therapeutics' Income from Continuing Operations averaged around -$52.2 million, with its median value being -$43.4 million (2023).
  • Data for Dianthus Therapeutics' Income from Continuing Operations shows a maximum YoY crashed of 94.65% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Dianthus Therapeutics' Income from Continuing Operations stood at -$28.6 million in 2022, then tumbled by 52.00% to -$43.4 million in 2023, then plummeted by 94.65% to -$84.5 million in 2024.